Biotechnology company conducting clinical studies focusing on researching, developing and delivering psychedelics to cure addiction Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) has commenced trading on the OTC Market in the United States.
Shares of the company started trading on the OTC Market on July 26 under the ticker symbol ‘AWKNF’ after receiving regulatory approval from the Financial Regulatory Authority (FINRA) to list its share for trading in the market.
The company says its shares will also continue trading on the NEO Exchange under the ticker symbol ‘AWKN’.
The company’s chief executive officer, Anthony Tennyson, acknowledges this as a remarkable milestone for the company one which will propel the company to the next stage and make it serve its clients better.
“With the commencement of trading on the OTC, Awakn has achieved another important milestone on our path to changing how addiction is treated and ultimately making a positive impact on the lives of our clients, their families, and communities. This additional capital markets exposure offers us greater visibility within the investment community in the U.S, which should enhance our liquidity and increase our access to institutional and retail investors. This support is extremely valuable to us as we progress both our therapeutic development programs and our delivery program, including our clinic’s rollout. We look forward to working with the team at OTC Markets Group on up-listing onto the OTCQB Venture Market,” said the CEO.
